Next we analyzed published data on 24 patients with CRC treated in second line with panitumumab-containing regimens [17] comparing this data with that in an additional 22 patients with CRC treated in second line with similar oxaliplatin or irinotecan-containing regimens with/without anti-EGFR antibodies. Here, EGFR is linked to colorectal carcinoma.